Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11710494 | 1.00 | POLB (0.54) | POLBCA12CA2CA9LTA4H | |
| SCHEMBL6964063 | 0.91 | CYP2D6 (0.63) | KMT2ACYP2D6CYP2C9CYP2C19CNR1 | |
| SCHEMBL8210487 | 0.89 | CA12 (0.53) | POLBCA12CA2CA9KMT2A | |
| SCHEMBL24095980 | 0.89 | CA12 (0.53) | POLBCA12CA2CA9KMT2A | |
| SCHEMBL8210490 | 0.89 | CA12 (0.53) | POLBCA12CA2CA9KMT2A | |
| SCHEMBL11714142 | 0.88 | HDAC8 (0.55) | CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL27498990 | 0.88 | CA12 (0.52) | POLBCA12CA2CA9KMT2A | |
| Hydrochloric Acid SCHEMBL3367304 | 0.88 | CA12 (0.52) | POLBCA12CA2CA9KMT2A | |
| SCHEMBL24322569 | 0.86 | NLN (0.57) | POLBCA12CA2CA9LTA4H | |
| SCHEMBL11712987 | 0.86 | NLN (0.57) | POLBCA12CA2CA9LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | POLB 4461/4885CA12 4750/4885CA2 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.